Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies

The overexpression of human epidermal growth factor 2 (HER2) in breast cancer (BC) has been associated with a more aggressive tumor subtype, poorer prognosis and shorter overall survival. In this context, the development of HER2-targeted radiotracers is crucial to provide a non-invasive assessment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hrynchak, Ivanna, Santos, Liliana, Falcão, Amílcar, Gomes, Célia M., Abrunhosa, Antero J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509594/
https://www.ncbi.nlm.nih.gov/pubmed/34639086
http://dx.doi.org/10.3390/ijms221910745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509594/
https://www.ncbi.nlm.nih.gov/pubmed/34639086
http://dx.doi.org/10.3390/ijms221910745

Ejemplares similares